Opinion on Biotech

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | » »|

Type Product title / description Pub Price
Expert View
Expert View

"The pill" goes natural with potential new bestseller

Teva has announced the EU approval of NOMAC/E2, the first monophasic contraceptive with natural estrogen. The perceived increased safety of natural estrogen and a global launch will drive sales of the product, making it a leading hormonal contraceptive brand. To maximize its potential, however, Teva needs to show improved safety over synthetic estrogen contraceptives in post-marketing studies.

Published By Datamonitor
03 Aug 2011
Expert View
Expert View

AAN 2011: Gilenya raises the bar for prospective MS market entrants

Datamonitor recently attended the 63rd American Academy of Neurology Annual Meeting in Honolulu, Hawaii, held over April 9-16, 2011. For another year running, developments in multiple sclerosis (MS) treatment research dominated proceedings. Below are the highlights of the conference's coverage of new multiple sclerosis drugs.

Published By Datamonitor
03 May 2011
Expert View
Expert View

AAN 2011: promising new Parkinson's treatment options may reduce motor fluctuations

Datamonitor recently attended the 63rd American Academy of Neurology Annual Meeting in Honolulu, Hawaii, held over April 9-16, 2011. Developments in late-stage pipeline agents for Parkinson's disease were a key talking point at AAN 2011. Below are the highlights of the conference's coverage of new Parkinson's drugs.

Published By Datamonitor
03 May 2011
Expert View
Expert View

AAN 2012: Novartis presents new data in an attempt to boost confidence in long-term use of Gilenya

In keeping with American Academy of Neurology meetings of recent years, multiple sclerosis once again dominated proceedings at AAN 2012. Novartis used the platform to present new data from the extension FREEDOMS II trial to support the long-term use of Gilenya, and provided Phase II results for siponimod in relapse remitting multiple sclerosis.

Published By Datamonitor
03 May 2012
Expert View
Expert View

AAN 2012: research shows value of early disease identification, but caution in treatment is advised

At AAN 2012, Merck Serono presented data from a long-term study showing that early Rebif treatment significantly reduced the clinical progression of multiple sclerosis. However, early intervention should be used cautiously to avoid unnecessary treatment.

Published By Datamonitor
03 May 2012
Expert View
Expert View

Abbott's flu vaccine business may represent a good deal for acquisitive drug makers

According to media reports, pharmaceutical company Abbott Laboratories is looking to auction off its influenza vaccine business in a deal that could be worth up to $600m. Abbott's established link to the Russian flu market and its advanced cell-based technology make the business an attractive prospect for would-be buyers, which may include the likes of GlaxoSmithKline and MedImmune.

Published By Datamonitor
29 Jun 2010
CommentWire
CommentWire

Actelion/GlaxoSmithKline: future of innovative orexin drug class in doubt

Actelion and GlaxoSmithKline have discontinued development of their Phase III insomnia candidate, almorexant, following a review of clinical data. The drug, an orexin receptor antagonist, had been widely regarded by leading sleep disorder specialists as an innovative and promising insomnia treatment. Termination of the drug's development casts doubt over the future of the drug class.

Published By Datamonitor
28 Jan 2011
Expert View
Expert View

Amgen and GlaxoSmithKline dominate proceedings at ECCEO-11 with Prolia presentations

Amgen's and GlaxoSmithKline's main goal at ECCEO-11 was to educate delegates regarding Prolia's unique mechanism of action and its key differentiators, such as its mode of administration and efficacy. Long-term safety data were presented in an attempt to address Phase III trial issues; however, it is unlikely that physicians will be persuaded to use Prolia as a first-line therapy in the near term.

Published By Datamonitor
06 Apr 2011
Expert View
Expert View

Amgen promotes novel offering at World Congress on Osteoporosis

The 2010 International Osteoporosis Foundation World Congress on Osteoporosis and 10th European Congress on Clinical and Economical Aspects of Osteoporosis and Osteoarthritis in May was the most important meeting of the year in the osteoporosis arena. While no new groundbreaking data for the drug were revealed, Amgen used the congress to promote its novel monoclonal antibody denosumab.

Published By Datamonitor
18 May 2010
CommentWire
CommentWire

Amgen: denosumab deal maximizes potential in tough European market

Amgen has announced that it has formed a partnership with GlaxoSmithKline to commercialize denosumab for the treatment of postmenopausal osteoporosis in Europe and emerging markets. While this partnership increases denosumab's potential in the EU, the challenge will be to convince payers that the new monoclonal antibody provides a clear clinical advantage over cheap and effective alternatives.

Published By Datamonitor
29 Jul 2009

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | » »|

No help is available.